Solutions
Advisory Services
Clinical Development
- Generics Development
- Clinical Operations
- Clinical Data Sciences
- Medical and Safety Services
- RWD & RWE Services
Post Marketing
- Safety Services
- Post marketing Studies
- Regulatory Affairs
Organizations approaching regulatory approval and commercialization face a rapid expansion in pharmacovigilance requirements, moving from development-focused clinical safety activities to full post-marketing obligations, global reporting, and continuous benefit–risk management. This transition demands strategic advisory to design a fit-for-p...
Biotech Innovation Meets Clinical Trial Excellence Biotech innovation is advancing rapidly but translating breakthroughs into approved therapies remains a challenge. Across biotech clinical trials, sponsors continue to face delays, recruitment bottlenecks and increasingly complex trial designs. These challenges persist in ophthalmology clinical tri...
Turning Regulatory Complexity into Strategic Advantage Hybrid and decentralized models are becoming the default architecture for modern clinical development. Yet, as innovation accelerates, regulatory alignment remains uneven, creating a new layer of complexity for sponsors operating across borders. A recent peer-reviewed publication in The Pharma ...
Real-world evidence (RWE) is emerging as a cornerstone of modern clinical development and regulatory strategy for patient-centric innovation. How is real-world evidence transforming clinical trials in Asia-Pacific? In her latest article published in PharmaFocus Asia, Yun Lu, Chief Science and Innovation Officer at Navitas Life Sciences, explores th...
Navitas has been awarded the EcoVadis Bronze Medal for the second consecutive year, showcasing the organization’s commitment to Environmental, Social and Governance (ESG) principles and responsible business practices. What is the EcoVadis Bronze Medal? EcoVadis is one of the world’s most recognized sustainability assessment platforms,...
The biopharmaceutical industry is approaching a defining moment. Scientific breakthroughs across cell and gene therapies, precision oncology and novel biologics are accelerating faster than the systems designed to test them. This perspective is informed by recent industry thought leadership, including insights published by McKinsey & Company on...
In an industry defined by scientific complexity, global regulatory shifts and rising expectations for speed and quality, pharma and biotech organizations increasingly rely on life sciences consulting services that offer both strategic foresight and operational depth. Navitas Life Sciences stands apart as a pharma and biotech advisory partner with t...
Patient registries have become one of the most powerful tools Foundations can use to advance research, improve care and amplify the patient voice. They inform real-world evidence generation. They guide standards of care. They influence policy, funding and therapeutic development. And yet, many registries fail quietly. Not because of poor intent or ...
From Regulatory Necessity to Strategic Advantage AI in Labeling is emerging as an important milestone. After all, labeling has long been one of the most critical yet understated functions in life sciences. For years, its primary mandate was to ensure compliance, reflect approved data accurately and meet regulatory expectations across markets. The w...
In life sciences outsourcing, few terms are used as interchangeably, and as confusingly, as Contract Research Organisation and Clinical Research Organisation. Both are commonly shortened to CRO, both support sponsors across drug development, and both play a critical role in bringing therapies to patients faster. So what actually differentiates a Co...